Transgenic breast cancer mouse models have confirmed that elevated signaling in the EGFR/HER2-PI3K-Akt pathway either by targeted Akt overexpression or HER2 overexpression in breast epithelial cells induces breast cancer development [18-20]. The gene discussed is ERBB2; the disease is breast carcinoma.